γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

BACKGROUND: Chk1 inhibitors are currently in clinical trials in combination with a range of cytotoxic agents and have the potential to potentiate the clinical activity of a large number of standard of care chemotherapeutic agents. Utilizing pharmacodynamic biomarkers to optimize drug dose and schedu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawlinson, Rebecca, Massey, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094550/
https://www.ncbi.nlm.nih.gov/pubmed/24996846
http://dx.doi.org/10.1186/1471-2407-14-483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094550/
https://www.ncbi.nlm.nih.gov/pubmed/24996846
http://dx.doi.org/10.1186/1471-2407-14-483

Ejemplares similares